ACAD — ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $268 million, an 11% year-over-year increase on an adjusted basis.
• DAYBUE Sales: $101 million, up 20% year-over-year, marking the highest growth since Q3 2024.
• NUPLAZID Sales: $167 million, a 6% increase year-over-year on an adjusted basis.
• Operating Expenses: R&D expenses were $76.9 million (down from $78.3 million in Q1 2025), while SG&A expenses rose to $171 million (up from $126.4 million).
• Cash Position: $851 million at the end of Q1, up from $820 million in Q4 2025.

2. Strategic Updates and Business Highlights

• DAYBUE STIX Launch: Strong early uptake with 250 prescriptions, 30% from treatment-naive or returning patients. The product is now broadly available in the U.S.
• NUPLAZID Demand: Strong referral growth of 11% year-over-year, with expectations for continued growth following a sales force expansion.
• Pipeline Developments: Anticipated Phase II readout for remlifanserin in Alzheimer's disease psychosis expected between August and October 2026. Phase III trial in Japan for trofinetide is also expected to yield results in the September to November timeframe.
• Market Positioning: DAYBUE is recognized as the standard of care for Rett syndrome, supported by a recent Delphi expert consensus.

3. Forward Guidance and Outlook

• 2026 Financial Guidance: Reaffirmed total revenue guidance of $1.22 billion to $1.28 billion.
• Sales Expectations: Anticipated back-end loading of revenue, with stronger contributions expected in the second half of the year from both DAYBUE and NUPLAZID.

4. Bad News, Challenges, or Points of Concern

• NUPLAZID Refill Delays: Some patients were slower to refill prescriptions in early 2026, impacting first quarter sales. However, this trend has normalized.
• Market Competition: Ongoing competitive pressures in the Alzheimer's treatment space, particularly with recent approvals for agitation treatments, which could affect market dynamics for remlifanserin.
• Leadership Transition: Elizabeth Thompson, EVP of R&D, announced her retirement by year-end, raising concerns about continuity in leadership during critical pipeline developments.

5. Notable Q&A Insights

• Pipeline Confidence: Management expressed confidence in the timelines for the Phase II study of remlifanserin, with enrollment nearing completion.
• Market Dynamics: Discussion on the differentiation between agitation and psychosis in Alzheimer's treatment, emphasizing the potential for multiple effective therapies in the market.
• Patient Engagement: Strategies to reengage approximately 1,000 patients who previously discontinued DAYBUE treatment were discussed, with a focus on the advantages of the new STIX formulation.
• Regulatory Considerations: Insights shared on the importance of biomarker confirmation in clinical trials for Alzheimer's, with implications for future regulatory submissions.

This summary encapsulates the key elements from ACADIA's Q1 2026 earnings call, highlighting both the company's achievements and the challenges it faces moving forward.